| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cyclo Therapeutics Inc. | Trappsol Cyclo - (TransportNPC) | Niemann-Pick Disease Type C | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| Cytodyn Inc | Leronlimab (PRO 140) | HIV | BLA Filing | Subcutaneous | Anti-HIV | |
| Cytodyn Inc | Leronlimab | Non-alcoholic steatohepatitis (NASH) | Phase 2 | Subcutaneous | Gastroenterology | |
| Cytodyn Inc | Leronlimab | Chronic inflammation | Phase 2 | Trial Planned | Subcutaneous | Immunology |
| Cytodyn Inc | Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab | CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Cytodyn Inc | Leronlimab | Relapsed/refractory micro-satellite stable colorectal cancer (CRC) | Phase 2 | Data Released | Subcutaneous | Oncology |
| Cytodyn Inc | Leronlimab (CD16) | Covid-19 (critically ill) | Phase 3 | Trial Discontinued | Subcutaneous | COVID-19 |
| Cytodyn Inc | Leronlimab | COVID-19 (critically ill) | Phase 3 | Subcutaneous | COVID-19 |